Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: A double-blind, randomized study with metformin

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 12, 2005, Pages 6523-6528

  Viljanen, Antti P M ^a   Virtanen, Kirsi A ^a   Järvisalo, Mikko J ^a   Hällsten, Kirsti ^a   Parkkola, Riitta ^a   Rönnemaa, Tapani ^a   Lönnqvist, Fredrik ^b   Iozzo, Patricia ^c   Ferrannini, Ele ^c   Nuutila, Pirjo ^a,d  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c CNR   (Italy)

^d TURKU PET CENTRE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METFORMIN; PLACEBO; ROSIGLITAZONE; WATER;

ADIPOSE TISSUE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HUMAN; HYPERINSULINEMIA; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIZATION; SUBCUTANEOUS TISSUE;

ADIPOSE TISSUE; AGED; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; PERFUSION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REGIONAL BLOOD FLOW; SUBCUTANEOUS TISSUE; THIAZOLIDINEDIONES;

EID: 28744458220     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-1073     Document Type: Article

References (46)

1. Saltiel AR, Olefsky JM 1996 Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669
2. Smith SA 1997 Peroxisomal proliferate-activated receptors and the regulation of lipid oxidation and adipogenesis. Biochem Soc Trans 25:1242-1248
3. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE 1995 Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333:550-554
4. Cusi K, Consoli A, DeFronzo RA 1996 Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81:4059-4067
5. Spiegelman BM 1998 PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514
6. Ciaraldi TP, Kolterman OG, Scarlett JA, Kao M, Olefsky JM 1982 Role of glucose transport in the postreceptor defect of non-insulin-dependent diabetes mellitus. Diabetes 31:1016-1022
7. Virtanen KA, Lönnroth P, Parkkola R, Peltoniemi P, Asola M, Viljanen T, Tolvanen T, Knuuti J, Rönnemaa T, Huupponen R, Nuutila P 2002 Glucose uptake and perfusion in subcutaneous and visceral adipose tissue during insulin stimulation in nonobese and obese humans. J Clin Endocrinol Metab 87:3902-3910
8. Garvey WT, Maianu L, Huecksteadt TP, Birnbaum MJ, Molina JM, Ciaraldi TP 1991 Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity. J Clin Invest 87:1072-1081
9. Freidenberg GR, Reichart D, Olefsky JM, Henry RR 1988 Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus. Effect of weight loss. J Clin Invest 82:1398-1406
10. Smith U, Axelsen M, Carvalho E, Eliasson B, Jansson PA, Wesslau C 1999 Insulin signaling and action in fat cells: associations with insulin resistance and type 2 diabetes. Ann NY Acad Sci 892:119-126
11. Virtanen KA, Hällsten K, Parkkola R, Janatuinen T, Lönnqvist F, Viljanen T, Rönnemaa T, Knuuti J, Huupponen R, Lönnroth P, Nuutila P 2003 Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 52:283-290
12. Laakso M, Edelman SV, Brechtel G, Baron AD 1990 Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 85:1844-1852
13. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD 1996 Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97:2601-2610
14. Bonadonna RC, Saccomani MP, Del Prato S, Bonora E, DeFronzo RA, Cobelli C 1998 Role of tissue-specific blood flow and tissue recruitment in insulin-mediated glucose uptake of human skeletal muscle. Circulation 98:234-241
15. Hällsten K, Virtanen KA, Lönnqvist F, Sipilä H, Oksanen A, Viljanen T, Rönnemaa T, Viikari J, Knuuti J, Nuutila P 2002 Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 51:3479-3485
16. Frayn KN 1999 Macronutrient metabolism of adipose tissue at rest and during exercise: a methodological viewpoint. Proc Nutr Soc 58:877-886
17. 18F]FDG) and PET in combination with microdialysis. Diabetologia 44:2171-2179
18. Miyazaki Y, He H, Mandarino LJ, DeFronzo RA 2003 Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes 52:1943-1950
19. 2O production system for heart and brain studies. J Labelled Comp Radiopharm 44(Suppl 1):S1066-S1068
20. 18F]fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27:235-238
21. Alenius S, Ruotsalainen U 1997 Bayesian image reconstruction for emission tomography based on median root prior. Eur J Nucl Med 24:258-265
22. Patlak CS, Blasberg RG 1985 Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab 5:584-590
23. DeFronzo RA, Tobin JD, Andres R 1979 Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223
24. Ruotsalainen U, Raitakari M, Nuutila P, Oikonen V, Sipilä H, Teräs M, Knuuti MJ, Bloomfield PM, Iida H 1997 Quantitative blood flow measurement of skeletal muscle using oxygen-15-water and PET. J Nucl Med 38:314-319
25. Pitkänen OP, Laine H, Kemppainen J, Eronen E, Alanen A, Raitakari M, Kirvelä O, Ruotsalainen U, Knuuti J, Koivisto VA, Nuutila P 1999 Sodium nitroprusside increases human skeletal muscle blood flow, but does not change flow distribution or glucose uptake. J Physiol 521:729-737
26. Tan GD, Fielding BA, Currie JM, Humphreys SM, Desage M, Frayn KN, Laville M, Vidal H, Karpe F 2005 The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 48:83-95
27. Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A, Yudkin JS, Ferrannini E 2004 Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 27:1349-1357
28. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P 2004 In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 27:484-490
29. Carey DG, Cowin GJ, Galloway GJ, Jones NP, Richards JC, Biswas N, Doddrell DM 2002 Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. Obes Res [Erratum (2002) 10:following table of contents] 10:1008-1015
30. Miyazaki Y, He H, Mandarino LJ, DeFronzo RA 2003 Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes 52:1943-1950
31. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Mäkimattila S, Yki-Järvinen H 2004 Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53:2169-2176
32. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA 2001 Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44:2210-2219
33. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF 2002 The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797-802
34. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI 2000 Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49:2063-2069
35. Wu MS, Johnston P, Sheu WH, Hollenbeck CB, Jeng CY, Goldfine ID, Chen YD, Reaven GM 1990 Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 13:1-8
36. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM 2000 Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 85:2767-2774
37. Spiegelman BM, Hu E, Kim JB, Brun R 1997 PPAR-γ and the control of adipogenesis. Biochimie 79:111-112
38. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J 1997 The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem 272:18779-18789
39. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J 1999 PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19:546-551
40. Iijima K, Yoshizumi M, Ako J, Eto M, Kim S, Hashimoto M, Sugimoto N, Liang YQ, Sudoh N, Toba K, Ouchi Y 1998 Expression of peroxisome proliferator-activated receptor γ (PPARγ) in rat aortic smooth muscle cells. Biochem Biophys Res Commun 247:353-356
41. Akbiyik F, Ray DM, Gettings KF, Blumberg N, Francis CW, Phipps RP 2004 Human bone marrow megakaryocytes and platelets express PPARγ and PPARγ agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 104:1361-1368
42. Vinik AI, Stansberry KB, Barlow PM 2003 Rosiglitazone treatment increases nitric oxide production in human peripheral skin: a controlled clinical trial in patients with type 2 diabetes mellitus. J Diabetes Complications 17:279-285
43. Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT 2004 Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 93:362-365
44. Nugent C, Prins JB, Whitehead JP, Savage D, Wentworth JM, Chatterjee VK, O'Rahilly S 2001 Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR-γ agonists is maintained in cells expressing a PPAR-γ dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR-γ activation. Mol Endocrinol 15:1729-1738
45. Mukherjee R, Hoener PA, Jow L, Bilakovics J, Klausing K, Mais DE, Faulkner A, Croston GE, Paterniti Jr JR 2000 A selective peroxisome proliferator-activated receptor-γ (PPARγ) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol Endocrinol 14:1425-1433
46. Ciaraldi TP, Kong AP, Chu NV, Kim DD, Baxi S, Loviscach M, Plodkowski R, Reitz R, Caulfield M, Mudaliar S, Henry RR 2002 Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes 51:30-36